Next Article in Journal
Serum Deprivation-Induced Human GM3 Synthase (hST3Gal V) Gene Expression Is Mediated by Runx2 in Human Osteoblastic MG-63 Cells
Next Article in Special Issue
Chalcone-Induced Apoptosis through Caspase-Dependent Intrinsic Pathways in Human Hepatocellular Carcinoma Cells
Previous Article in Journal
Alisertib Induces Cell Cycle Arrest, Apoptosis, Autophagy and Suppresses EMT in HT29 and Caco-2 Cells
Previous Article in Special Issue
Current Status of Herbal Medicines in Chronic Liver Disease Therapy: The Biological Effects, Molecular Targets and Future Prospects
Open AccessReview

EGFR Signaling in Liver Diseases

by and *
Institute of Cancer Research, Department of Medicine I, Comprehensive Cancer Center, Medical University of Vienna, Borschkegasse 8a, A-1090 Vienna, Austria
Author to whom correspondence should be addressed.
Academic Editor: Johannes Haybaeck
Int. J. Mol. Sci. 2016, 17(1), 30;
Received: 21 November 2015 / Revised: 17 December 2015 / Accepted: 21 December 2015 / Published: 29 December 2015
(This article belongs to the Collection Molecular Mechanisms of Human Liver Diseases)
The epidermal growth factor receptor (EGFR) is a transmembrane receptor tyrosine kinase that is activated by several ligands leading to the activation of diverse signaling pathways controlling mainly proliferation, differentiation, and survival. The EGFR signaling axis has been shown to play a key role during liver regeneration following acute and chronic liver damage, as well as in cirrhosis and hepatocellular carcinoma (HCC) highlighting the importance of the EGFR in the development of liver diseases. Despite the frequent overexpression of EGFR in human HCC, clinical studies with EGFR inhibitors have so far shown only modest results. Interestingly, a recent study has shown that in human HCC and in mouse HCC models the EGFR is upregulated in liver macrophages where it plays a tumor-promoting function. Thus, the role of EGFR in liver diseases appears to be more complex than what anticipated. Further studies are needed to improve the molecular understanding of the cell-specific signaling pathways that control disease development and progression to be able to develop better therapies targeting major components of the EGFR signaling network in selected cell types. In this review, we compiled the current knowledge of EGFR signaling in different models of liver damage and diseases, mainly derived from the analysis of HCC cell lines and genetically engineered mouse models (GEMMs). View Full-Text
Keywords: EGFR; liver; partial hepatectomy; hepatocellular carcinoma EGFR; liver; partial hepatectomy; hepatocellular carcinoma
Show Figures

Graphical abstract

MDPI and ACS Style

Komposch, K.; Sibilia, M. EGFR Signaling in Liver Diseases. Int. J. Mol. Sci. 2016, 17, 30.

AMA Style

Komposch K, Sibilia M. EGFR Signaling in Liver Diseases. International Journal of Molecular Sciences. 2016; 17(1):30.

Chicago/Turabian Style

Komposch, Karin; Sibilia, Maria. 2016. "EGFR Signaling in Liver Diseases" Int. J. Mol. Sci. 17, no. 1: 30.

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Search more from Scilit
Back to TopTop